PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition
AssigneeMedical Diagnostic Laboratories, LLC
InventorsLyndi Rice, Michelle Pusey, Ewa Wandzioch, Sophie Marie Genevieve Bail, Amy Lynn Werda
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
Claims10
A method for determining whether a woman has endometrial cancer, comprising the steps of:
- (a) obtaining an endometrial tissue from a woman suspected of having an increased risk of endometrial cancer;
- (b) obtaining a normal endometrial tissue;
- (c) treating said endometrial tissue obtained in step (a) with a lysis buffer to prepare a first lysate;
- (d) treating said endometrial tissue in obtain step (b) with a lysis buffer to prepare a second lysate;
- (e) performing a Western blot or an ELISA to quantify PME-1 protein expression level in said first lysate and PME-1 protein expression level in said second lysate;
- (f) comparing said PME-1 protein expression level in said first lysate with said PME-1 protein expression level in said second lysate;
- and
- (g) diagnosing said woman as having endometrial cancer, if there is an increased PME-1 protein expression level in said endometrial tissue obtained in step (a) relative to said normal endometrial tissue obtained in step (b),
- wherein said Western blot or ELISA uses a goat, rabbit or mouse antibody.
A method of detecting PME-1 in a patient, comprising the steps of:
- (a) obtaining an endometrial tissue from a woman suspected of having an increased risk of endometrial cancer;
- (b) performing a Western blot or an ELISA to on the endometrial tissue to quantify PME-1 protein expression level in said tissue.
Dependencies are inferred from the claim text.